Maryland CRO ABL has signed a deal with Expression Therapeutics to to handle cell line development studies and help the biotech produce a treatment for hemophilia A. The candidate, a recombinant factor VIII replacement therapy, is in preclinical testing, and ABL is on board to conduct optimization studies to support large-scale manufacturing of Expression's drug, paving the way for human trials. More